Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto
The FDA rejected the therapy after the AdCom raised efficacy and ethical concerns in Lykos’ trials of its lead pipeline drug.
The FDA rejected the therapy after the AdCom raised efficacy and ethical concerns in Lykos’ trials of its lead pipeline drug.
What's Your Reaction?
